About ImpediMed


ImpediMed is a medical device world leader with a focus on providing fluid and body composition measurements that are non-invasive, highly accurate and simple to operate. Our bioimpedance spectroscopy technology is unique in that it scans a wide frequency up to 1000kHz taking readings from 256 points- making this device the most accurate bioimpedance spectroscopy device available.

ImpediMed devices are currently used in both the clinical and research settings with future applications being deve-
loped for home use.

ImpediMed has over 15 years of clinical experience supporting healthcare professionals in the assessment of secondary unilateral lymphedema of the limbs. ImpediMed’s devices are used in a variety of settings to aid surgeons, oncologists, therapists, and radiation oncologists.

Our research devices are thought of as a gold standard measurement system for non-invasive fluid and body composition measurement, used in both animals and human research.


With offices in Australia, Europe and the United States, ImpediMed is a global company pioneering the next generation of devices using BIS technology. ImpediMed is currently in the process of developing SOZO, a BIS device that is accurate and clinically useful in monitoring and managing fluid status and body composition to provide users with the resources they need to improve their overall health.

During the development of SOZO, ImpediMed continuously strives to uphold its mission to improve patients’ lives by providing solutions that will allow for a deeper understanding of the human body and the importance of fluid status and body composition in all living things.

Save, Heal, Create.

Sozo is originally a Greek word that simply means “to save” or “to rescue”. It also means “creation” or “to imagine” in Japanese. In the process of developing SOZO, ImpediMed moves forward with three goals in mind:


SOZO will allow for pre-operative clinical assessment of secondary lymphedema in cancer survivors that may prevent the condition from becoming a lifelong management issue.


SOZO will help users gain an in-depth understanding of their bodies and allows for disease management and continual health monitoring thus improving the quality of life overall.


SOZO’s BIS technology is unique and clinically proven in the monitoring and measuring of fluid status and body composition, giving patients the opportunity to take charge of their health.

SOZO has not yet been FDA-cleared for this indication in the US and is not yet available for sale for the assessment of lymphedema.

Learn more about ImpediMed’s history and products at www.impedimed.com.

Australian Corporate

Office Unit 1,
50 Parker Court Pinkenba,
QLD 4008 Australia

United States Office

5900 Pasteur Court,
125 Carlsbad,
CA 92008 USA

US Regional Office

2901 Metro Drive,
Suite 225 Bloomington,
MN 55425 USA

European Regional Office

Adrianoupoleos 24,
55133 Greece